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Background: This study aims to compare severity criteria defined by the Remission in Schizophrenia Working
Group (RSWGcr) with other criteria in relation to functional and neurocognitive outcome.
Methods: 112 chronic psychotic outpatients were examined. Symptomatic remission according to RSWGcr was
compared with the outcome achieved using criteria based on PANSS Positive and Negative Scales (PANSS-PNScr)
and the entire PANSS (PANNS-TScr).
Results: Remission rates were 50%, 35% and 23% respectively at RSWGcr, PANSS-PNScr and PANNS-TScr; functional
remission rates were 32%, 42% and 54%. Sensitivity, specificity, predictive value and ROC analysis demonstrated the
superiority of PANSS-PNScr in identifying patients with higher functional and cognitive outcomes. Regression
analysis showed a significant predictive effect of PANSS-TScr on functioning. General linear model analyses
demonstrated significantly higher mean scores at PSP and BACS for patients remitted according to PANSS-TScr.
Conclusion: The use of more restrictive severity criteria of remission seems to be associated with improved
identification of truly remitted patients.Background
It is widely acknowledged that recovery may be achieved
even in subjects affected by serious mental illnesses.
However, the dimensions to be included in the concept
of recovery are still the object of ongoing debate [1]. It
is generally assumed that recovery will comprise both
objective and subjective [2] components, otherwise de-
fined as clinical and personal domains [3]; the objective
component generally refers to clinical outcomes which
are evaluated by means of operationally defined criteria;
subjective recovery refers to the ongoing process of
positive changes in an individual’s subjective experience
of themselves as human beings [1]. Clinical objective
and personal subjective recovery are largely independent
phenomena [4] and both should be considered as targets
for therapeutic interventions in schizophrenia and related
disorders. Symptom remission represents the fundamental* Correspondence: bcarpini@iol.it
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reproduction in any medium, provided the orcomponent underlying clinical recovery, together with
improved functioning [1], and is viewed as the main target
for psychopharmacological interventions [5]. Up until fairly
recently, a univocal method for the assessment of remission
was lacking; to this aim, a significant step forward was rep-
resented by publication of the Remission in Schizophrenia
Working Group criteria (RSWGcr) [6] which proved to be
conceptually viable and easy to use both in clinical trials
and clinical practice [7].
According to RSWGcr [6] clinical remission is based on
a symptom severity criterion comprising eight items of the
PANSS scale chosen as being the most diagnostic-specific
for schizophrenia, and a duration criterion, thus excluding
symptom domains not diagnostically relevant for the
disorder. As PANSS scale provides ratings investigating
not only symptom severity per se but also functional
impairment, a score of “mild” or better (i.e. 3 points or less)
at all eight “core” symptoms was considered sufficiently
representative of a level of impairment consistent with
symptomatic remission of the disorder [7]. According to
recent reviews [8,9] reported remission rates vary widelytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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severity criterion alone in the majority of studies [9]. A
number of studies have demonstrated the validity of these
remission criteria using two different approaches, namely
comparison of different definitions of symptomatic remis-
sion and association of remission criteria with various out-
come dimensions, mainly overall symptomatic status and
functional outcome [10]. However, several recent studies
seem to highlight the potential limitations of severity
criteria as currently conceived in predicting functioning
and other important outcome variables. Indeed, a study
aimed at investigating symptomatically remitted and non
remitted patients demonstrated a significantly better level
of functioning for remitted patients, although the latter
continued to display significant areas of inadequate func-
tioning, low levels of subjective wellbeing and moderate-
severe emotional distress [11]. Moreover, a recent study
attempting to provide an ecological validation for the
symptomatic remission criterion, showed how although
remitted patients reported fewer positive symptoms, better
mood states and partial recovery of reward experience,
remission status was not related to functional recovery
[12]. Starting from these premises, and taking into account
the need for further investigation into the validity of current
criteria for symptomatic remission, the present study
was devised to compare the efficacy of three different
and increasingly “stringent” sets of criteria in evaluating




In the context of an ongoing study on recovery [13],
all outpatients with a diagnosis of schizophrenia or
schizoaffective disorder according to DSM-IV-TR attending
a university community mental health centre (CMHC) in
the year 2010 were enrolled consecutively. Patients with
other comorbid psychiatric and or somatic disorders were
also included in the study, with the exception of those
with comorbid mental retardation or organic brain diseases.
Standard care was provided to patients as in CMHCs
in Italy (clinical monitoring at least on a monthly basis;
pharmacological treatment; home care when required,
psychosocial and rehabilitation interventions tailored to
patient’s needs). The study was approved by the institu-
tional Ethical Committee of Local Health Unit of Cagliari
(Italy) and was conducted according to national laws.
Ratings
Evaluation was performed by residents in psychiatry using
a set of standardized methods of evaluation, after adequate
training in use of all instruments adopted. Personal and
social data, and clinical history were collected through a
structured interview purpose-developed for the study.After providing informed consent, patients were interviewed
by means of the Italian versions [14,15] of SCID-I [16]
and SCID-II [17]; inter-rater reliability, assessed using
Cohen’s K before the study, was higher than 0.80. Symptom
severity was evaluated using the Italian version [18] of
PANSS (Positive and Negative Syndrome Scale) [19]; as
previously, interviews were conducted by residents in
psychiatry trained in use of the instrument using the
Italian version [20] of SCI-PANSS (Structured Clinical
Interview for the positive and Negative scale) [21]; ratings
were based on criteria indicated in the PANSS Manual
[22]; inter-rater reliability of PANSS evaluations in terms
of ICC (Intraclass correlation coefficient) for the PANSS
total score ranged from 0.65 to 0.95. Wherever possible,
PANSS assessment included a standard section of queries
addressed to treating clinicians and to caregivers. RSWG
criteria [6] based on ratings at 8 focal symptoms in posi-
tive, negative and general psychopathology subscales of
PANSS (P1, P2, P3, N1, N4, N6, G5, G9) were applied for
clinical remission; patients were judged to be in clinical
remission according to a severity criterion (scores obtained
at each of these items had to be ≤ 3 points, indicating mild
severity of symptoms). Due to the cross-sectional nature
of the study, clinical remission was evaluated taking into
account the severity criterion alone, excluding the duration
criterion (remission maintained for six-months). Moreover,
two more restrictive severity criteria for remission were
adopted: obtaining scores ≤3 at each item of Positive
and Negative (PANSS-PNScr) or of Positive, Negative and
General Psychopathology Scale of PANSS (PANSS-TScr).
The reason for this choice is that the scope of the study
was to test the performance of PANSS in evaluating symp-
tom remission, as this scale is generally used in common
clinical practice; as a consequence, we decided to use the
three subscales originally identified by the developers of
the instrument, in spite of the fact that several factor
analyses have underlined how a five-factor model better
characterizes PANSS data [23].
Overall clinical status was also evaluated by the Clinical
Global Impression-Schizophrenia scale (CGI-SCH) [24].
Cognitive functioning was evaluated by means of the Brief
Assessment of Cognition in Schizophrenia scale (BACS)
[25], using five of the six subtests, namely list learning,
digit sequencing, category instances and controlled oral
word association test, symbol coding and executive func-
tions; a gender/age/education adjusted score and thus an
equivalent score were calculated [26]. Mini Mental State
Examination test (MMSE) [27] was administered, calculat-
ing an age/education adjusted score [28]. Functioning was
evaluated by PSP (Personal and Social Performance Scale)
[29], which assesses social functioning of patients in 4
main areas: socially useful activities, personal and social
relationships, self-care and disturbing/aggressive be-
haviours. A non-standardized interview was conducted
Pinna et al. BMC Psychiatry 2013, 13:235 Page 3 of 10
http://www.biomedcentral.com/1471-244X/13/235with the patient, caregivers (when available) and the
treating physician, with the aim of assessing functioning by
means of PSP. A comprehensive overall score ranging from
1 (maximum dysfunction) to 100 (maximum functioning)
was attributed, based on score obtained at each single
area. A total score exceeding 70 indicates a condition of
“functional remission”, with scores being related to overall
good functioning.
Statistical analysis
Categorical data were analyzed using Pearson’s χ2 Test
or Fisher’s exact test; continuous variables were assessed
by means of Student’s”t” test for independent samples.
The magnitude of differences in mean scores obtained at
different rating scales used in the study was calculated by
means of Cohen’s “d”. To evaluate differences in remission
rates observed according to the different proposed criteria,
McNemar Test for matched pairs of subjects was used.
ROC analysis, with Sensitivity, Specificity and Predictive
Value Analysis of the ability of different definitions of
Remission to predict good outcomes were calculated.
Moreover, multiple linear regressions and General Linear
Model Analysis were employed to investigate whether the
proposed definitions of clinical remission would predict
functional and cognitive outcomes. Data analyses were
performed using SPSS 19.0. Level of significance was set
at a p value ≤ 0.05 for two-tailed hypothesis.
Results
Baseline characteristics
The sample comprised 112 patients: 80 males (71.4%)
and 32 (28.6%) females, forty-six (41.1%) schizophrenic
and sixty-six (58.9%) schizoaffective subjects (58.9%); mean
age was 43.5 +/− 9.42 years (range 25–68); mean years of
education 10.84+/−3.9 (range 4–24); 97 subjects (86.6%)
were single; 83 (74.1%) unemployed.
Clinical remission
To evaluate differences in remission rates, McNemar Test
for matched pairs of subjects was used. The proportion of
remitted patients was significantly higher using RSWGcr
(50%), compared to both PANSS- PNScr (34.8%) and
PANSS-TScr (23.2%) (p < .0001 and p < .0000 respectively);
the frequency of remission was significantly (p < .0008)
higher with PANSS-PNScr respect to PANSS-TScr. Remit-
ted and non-remitted patients featured several significantly
different characteristics as shown in Table 1. A higher pro-
portion of remitted patients, increasing in line with strin-
gency of criteria adopted, was found among schizoaffective
subjects, although differences were generally not statistically
significant. Mean scores at CGI-SCH were all significantly
higher among non-remitted patients yielding effects of
medium (Cohen’s d 0.5-1) or large (Cohen’s d > 1) magni-
tude for the majority of scales, independent of remissioncriteria (Table 2). Significantly higher mean scores were
also found among non-remitted patients at PANSS, with
effects of large magnitude, independent of remission
criteria (Table 2). Significantly different mean scores were
detected for cognitive functioning (Table 3), using both
PANSS-PNScr and PANSS-TScr, between remitters and
non remitters at MMSE and at almost all subtests of
BACS, with effects of medium magnitude, independent of
criteria adopted.
Functioning
Twenty-three patients (20.5%) were found to be in
functional remission. The rates of “functionally remitted”
patients detected were invariably and significantly higher
among clinically remitted patients (Table 4); functional
remission increased from 32.1% among patients in clinical
remission according to RSWGcr, to 42.1% among remitted
subjects according to PANSS-PNScr, reaching 53.8%
among the remitted according to PANSS-TScr. Rates
of patients reaching a score < 3 (substantial absence of
impairment) at each PSP subscale were significantly higher
among clinical remitters, independent of the criterion
adopted; similarly, an increasing proportion of patients
showing no impairment was detected with more stringent
criteria (PANNS-PNScr and PANSS-TScr). Mean scores
at PSP subscales were all significantly higher among non-
remitters, indicating poorer functioning, independent
of criteria; even mean PSP total score was significantly
lower among non-remitters, independent of remission
criteria. Magnitude of effect sizes increased on a par with
stringency of clinical remission adopted, at least with
regard to PSP socially useful activities, social relationships
and total scale.
Prediction of functional outcome and cognitive status
To investigate whether the criteria proposed for clinical
remission would reflect differences in functional out-
come and cognitive status, diagnostic test evaluations
were performed.
For global functioning, patients were classified as remit-
ted/non remitted based on PSP total score. For cognitive
performances, equivalent scores for each subtest of BACS
were calculated, based on normative data from an Italian
sample and the mean used as a measure of general cogni-
tive ability, setting a cut-off of 1. RSWGcr, PANSS-PNScr
and PANSS-TScr were compared on their ability to identify
patients with better outcomes, using sensitivity, specificity
and predictive value analysis. Youden’s index and the area
under the receiver operating characteristic curve (AUROC)
were also calculated to quantify performances of the three
diagnostic criteria.
Results are shown in Table 5. Although positive pre-
dictive values are low for all definitions, as both good
functional and cognitive outcomes occur at lower rates
Table 1 Sociodemographic characteristics of remitted and non-remitted patients according to different criteria
Items Criteria of remission Remitted Non-remitted Statistics (df)
Education (years) SWGC* 11.55 (4.16) 10.13 (3.43) t(110) = 1.981, p = .05
(Means ± SD) PANSS PNS** 12.59 (4.09) 9.90 (3.42) t(110) = 3.697, p < .0001
PANSS TS*** 13.38 (4.13) 10.07 (3.45) t(110) = 4.094, p < .0001
Occupation (unemployed) N (%) SWGC* 36 (64.3%) 47 (83.9%) Chisq(1) = 9.775, p < .0001
PANSS PNS** 22 (56.4%) 61 (83.6%) Chsq(1) = 8.402, P = .004
PANSS TS*** 14 (53.8%) 69 (80.2%) ChiSq(1) = 21.694, P < .0001
Course of illness (continuous + episodic
with residual symptoms) N (%)
SWGC* 39 (69.6%) 50 (89.3%) Chisq(1) = 9.560, p = .008
PANSS PNS** 25 (64.1%) 64 (87.8%) Chisq(1) = 9.879, p = .007
PANSS TS*** 15 (57.7%) 74 (86.1%) Chisq(1) = 12.611, p = .002
Duration of illness (months) SWGC* 163.68 (100.01) 227.48 (112.58) t(110) = −3.171, p = .002
(Means ± SD) PANSS PNS** 138.10 (87.88) 226.29 (109.93) t(110) = −4.323, p < .0001
PANSS TS*** 134.58(102.30) 214.02(017.03) t(110) = −3.350, p = .001
*SWGC Schizophrenia Working Group Severity Criterion.
**PANSSPNS PANSS Positive and Negative Scores Severity Criterion.
***PANSSTS PANSS TOTAL Score Severity criterion.
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AUROC and Youden’s J were observed for the definition
based on PANSS-PNScr. Multiple linear regressions were
employed to assess whether the proposed definitions of
clinical remission would predict outcomes. Remission
status according to PANSS-TScr was used as categorical
predictor and continuous measures of functioning (PSP
total score) and cognition (BACS mean equivalent score)
as dependent variables, with remissions according to
RSWGcr and PANSS-PNScr as covariates. This type of
analysis, used by Cassidy et al. [30], allows to evaluate
whether RSWGcr alone or PANSS-PNScr continue to
contribute to the prediction of functioning and cognitive
status when PANSS-TScr remission is taken into account.
Regression on functional outcome showed a significant
predictive effect only for PANSS-TScr remission (p = .005,
β = .36), while neither RSWGcr nor PANSS-PNScr alone
were significant predictors of functioning. The explained
variance for the model was moderate (R [2] = .26). The
analysis on cognitive outcome showed no significant
predictor effect for any of the remission criteria used.
To further investigate the effect of clinical remission
according to the different criteria proposed on functional
and cognitive outcomes, a categorical variable defining
progressive achievement of different criteria of remission
was created. Patients were divided into 4 classes: not
remitted, remitted only according to RSWGcr, remitted
according to PANSS-PNScr but not PANSS-TScr and
remitted according to PANSS-TScr. General linear model
analyses were then performed with remission class as
independent factor and functional and cognitive outcomes
as dependent variables, respectively. The remission class
showed a significant effect on PSP total score (F = 12.35,
p < .000, R [2] = .26). Post-hoc analysis with Tukey HSDrevealed a significant difference between patients remitted
according to PANSS-TScr and both non-remitted patients
(p = .0001) and patients who achieved remission only
according to RSWGcr (p = .01).
A significant effect of remission class was also observed
for cognitive abilities (F = 4.50, p = .005, R [2] = .13), evalu-
ated as mean equivalent score of BACS subtests. Post-hoc
analysis with Tukey HSD revealed a significant difference
between patients remitted according to PANSS-TScr and
both non-remitted patients (p = .035) and patients who
achieved remission only according to RSWGcr (p = .035).
Discussion
The RSWG remission criteria have previously been com-
pared with criteria proposed by other authors [10]. Other
studies have evaluated RSWGcr versus a modified version
in terms of number of items included [31] or cut-off scores
at each core item [32]. One study focused on the evaluation
of accuracy of RSWGcr using PANSS total score as a
“golden standard” [33]. Finally, another study [30] com-
pared four definitions of remission based upon severity
scores at SAPS and SANS instead of PANSS. To our
knowledge, this is the first study to compare RSWGcr
with their modified versions, by extending the number
of items of PANSS used to evaluate remission.
In our sample 50% of subjects were in clinical remission
according to RSWGcr [6], a proportion that decreased sig-
nificantly by approximately one third using PANSS-PNScr,
and was halved when adopting PANSS-TScr. These results
are in contrast with those of van Os et al. [31] who found
no substantial change in remission rates when including
two PANSS items (namely, depression and suicidality) to
the eight “core symptoms”. This discrepancy however may
be explained considering that we adopted more stringent
Table 2 Mean scores ± sd at clinical scales of remitted and non-remitted patients according to different criteria
Items Criteria of remission Remitted Non-remitted Statistics (df)/Cohen’s d
CGI-S positive symptoms SWGC* 1.60 (0.95) 2.95 (1.42) t(110) = −5.853, p < .0001/1.17
PANSS PNS** 1.47 (0.89) 2.79 (1,41) t(110) = 4.860, p < .0001/1.04
PANSS TS*** 1.27 (0.67) 2.59 (1.39) t(110) = 4.678,p < .0001/1.209
CGI-S negative symptoms SWGC* 1.78 (0.91) 3.36 (1.27) t(110) = 7.478,p < .0001/1.43
PANSS PNS** 1.68 (0.93) 3.04 (1.32) t(110) = −5.650, p < .0001/1.19
PANSS TS*** 1.54 (0.71) 2.92 (1.36) t(110) = 4.948,p < .0001/1.20
CGI-S depressive symptoms SWGC* 1.71 (0.85) 2.36 (1.31) t(110) = 3.076,p = .003/0.58
PANSS PNS** 1.70 (0.90) 2.21 (1.24) t(110) = −2.185 p = .03/0.46
PANSS TS*** 1.38 (0.64) 2.29 (1.30) t(110) = 3.423p = .001/0.88
CGI-S cognitive symptoms SWGC* 1.84 (1.03) 3.18 (1.20) t(110) = 6.298,p < .0001/1.19
PANSS PNS** 1.66 (0.91) 2.96 (1.26) t(110) = 5.631,p < .0001/1.18
PANSS TS*** 1.65 (0.98) 2.78 (1.28) t(110) = 4.134p < .0001/0.99
CGI-S overall severity SWGC* 2.45 (0.95) 3.82 (0.76) t(110) = 8.309,p < .0001/1.59
PANSS PNS** 2.34 (0.96) 3.56 (0.92) t(110) = 6.479p < .0001/1.29
PANSS TS*** 2,12 (0.82) 3.49 (1.01) t(110) = 6.305,p < .0001/1.49
PANSS positive scale SWGC* 8.96 (2.09) 14.39 (4.35) t(110) = 8.417,p < .0001/1.59
PANSS PNS** 8.51 (1.71) 13.37 (4.40) t(110) = 6.617p < .0001/1.45
PANSS TS*** 8.19 (1.77) 12.73 (4.36) t(110) = 5.168p < .0001/1.36
PANSS negative scale SWGC* 10.57 (3.65) 18.70 (5.85) t(110) = 8.803,p < .0001/1.66
PANSS PNS** 9.64 (2.91) 17.30 (6.07) t(110) = 7.420,p < .0001/1.61
PANSS TS*** 9.58 (3.03) 16.16 (6.30) t(110) = 5.139,p < .0001/1.33
PANSS general psychopathology SWGC* 21.98 (4.87) 32.68 (7.48) t(110) = 8.964,p < .0001/1.69
PANSS PNS** 22.13 (5.13) 30.11 (8.31) t(110) = 5.462,p < .0001/1.15
PANSS TS*** 19.92 (3.58) 29.57 (7.98) t(110) = 5.972,p < .0001/1.66
PANSS Total scale SWGC* 41.52 (7.92) 65.77 (13.87) t(110) = 11.354,p < .0001/1.69
PANSS PNS** 40.28 (7.85) 60.78 (15.58) t(110) = 7.697,p < .0001/1.66
PANSS TS*** 37.69 (6.61) 58.47 (15.65) t(110) = 6.578,p < .0001/1.75
*SWGC Schizophrenia Working Group Severity Criterion.
**PANSSPNS PANSS Positive and Negative Scores Severity Criterion.
***PANSSTS PANSS TOTAL Score Severity Criterion.
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Our results are somewhat similar to those obtained by
Beitinger et al. [32] who reanalysed data from six anti-
psychotic trials applying more stringent criteria with regard
to cut-off scores used by RSWGcr; indeed, the frequency
of remitted patients using the original RSWGcr was ap-
proximately 42% in both medium-term and long-term
studies; using scores ≤ 2, remitted subjects were 16% and
13%, respectively; using a score of 1 they were respectively
3.4% and 5%. Based on these results the authors concluded
that a choice of severity score ≤3 was a “realistic” choice,
given that “more stringent thresholds yield remission
frequencies that are not realistic”. In our study, not based
on different scoring thresholds but rather on an extension
of the number and type of PANSS items considered, a
significant reduction of remission rates was obtained using
alternative criteria, but which was not so marked as to beunrealistic. Moreover, clinical status evaluated by PANNS
and CGI was invariably significantly better among remit-
ted patients, independent of remission criteria adopted. It
is noteworthy that only a few significant differences were
detected in mean scores obtained at BACS between remit-
ters and non remitters using SRWGcr; on the contrary,
significant differences were detected in mean scores of al-
most all BACS subtests and MMSE between remitters and
non-remitters using both PANSS-PNScr and PANSS-TScr,
indicating a better neurocognitive functioning among
patients judged as being in clinical remission according
to the more selective criteria adopted in this study. This
evidence seems to be of relevance, as cognitive perform-
ance is a strong predictor of functioning [34], and the best
levels of functioning were found among patients consid-
ered to be remitted according to the alternative criteria
of remission.
Table 3 Mean score ± sd at Neuropsychological Tests in remitted and non-remitted patients according to
different criteria
Items Criteria of remission Remitted Non-remitted Statistics (df)/Cohen’s d
MMSE Total score SWGC* 26.80 (2.71) 25.02 (4.42) t(110) = 2.576,p = .011/0.485
PANSS PNS** 27.33 (2.61) 25.15 (4.06) t(110) = 3.033,p = .003/0.638
PANSS TS*** 27.62 (2.47) 25.40 (3.93) t(110) = 2.713,p = .008/0.676
BACS list learning SWGC* 9.31 (4.77) 9.92 (4.59) t(99) = −.652,p = 0.516/NA°
PANSS PNS** 9.10 (5.24) 9.89 (4.35) t(99) = −.806,p = 0.422/NA°
PANSS TS*** 8.62 (5.42) 9.94 (4.38) t(99) = 1.236,p = 0.219/NA°
BACS Digit sequencing task SWGC* 14.75 (6.06) 11.26 (6.19) t(99) = 2.86,p = .005/0.571
PANSS PNS** 16.30 (5.65) 11.23 (6.01) t(99) = 4.112p < .0001/0.969
PANSS TS*** 17.31 (5.47) 11.56 (5.98) t(99) = 4.247p < .0001/1.00
BACS Verbal Fluency/category istances SWGC* 9.89 (4.98) 8.10 (4.96) t(99) = 1.801,p = .075/0.360
PANSS PNS** 10.66 (4.27) 8.10 (5.20) t(99) = 2.479,p = .014/0.538
PANSS TS*** 10.75 (4.21) 8.40 (5.16) t(99) = 2.056,p = .042/0.499
BACS Verbal FluencyControlled Oral Words ass.test SWGC* 15.05 (3.89) 14.50 (5.49) t(99) = 0.569 p = .571/NA°
PANSS PNS** 15.46 (4.31) 14.41 (4.96) t(99) = 1.061 p = .27/NA°
PANSS TS*** 15.21 (4.89) 14.63 (4.73) t(99) = 0.536 p = .593/NA°
BACS Symbol coding SWGC* 32.60 (13.64) 28.60 (12.29) t(99) = 1.549,p = 0.125/NA°
PANSS PNS** 36.10 (12.87) 27.67 (12.29) t(99) = 3.228,p = .002/0.669
PANSS TS*** 37.85 (12.48) 28.20 (12.43) t(99) = 3.263,p = .001/0.774
BACS Tower of London SWGC* 11.38 (5.98) 9.5 (6.53) t(99) = 1.445,p = 0.152/NA°
PANSS PNS** 12.80 (5.44) 9.25 (6.33) t(99) = 2.815,p = .006/0.601
PANSS TS*** 13.16 (5.65) 9.60 (6.21) t (99) = 2.536,p = .013/0.599
*SWGC Schizophrenia Working Group Severity Criterion.
**PANSSPNS PANSS Positive and Negative Scores Severity Criterion.
***PANSSTS PANSS TOTAL Score Severity Criterion.
°NA not assessed in absence of significant difference.
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compared with RSWGcr, particularly to assess impact
produced on functioning. Approx. 20% of subjects were
found to be “functionally remitted”; when functioning
was evaluated on the basis of clinical remission status, a
substantial increase in rates of functional remission was
observed, ranging from 32.1% in patients clinically remitted
according to RSWGcr, to 42.1% among patients remitted
according to PANSS-PNScr, with a peak of 53.8% among
patients remitted according to PANSS-TScr. Thus, by
broadening the number and type of PANSS items used
to evaluate remission, the ability to identify well-functioning
patients was markedly improved. Confirmation of this
was obtained by evaluating the proportion of patients in
clinical remission who were devoid of significant im-
pairment at each single dimension of PSP; with regard
to “socially useful activities”, this proportion increased
from 32% using RSGWcr to 42% using PANSS-PNScr
and 53.8% using PANSS-TScr. The rates of patients
devoid of impairment in “social relationships” were 46%,
58.9% and 69.2%, respectively. Furthermore, 36% ofpatients viewed as remitted according to RSWGcr were in
employment, as were 44% of individuals remitted accor-
ding to PANSS-PNScr, and 46% of remitters according to
PANNS-TScr. Even when taking into consideration, as
pointed out by Lambert et al. [10] that “functioning in
schizophrenia…is probably influenced by other factors
independent from remission status”, the results obtained
are quite impressive, being achieved in the same set of
patients, but with employment status clearly changing
according to the way in which clinical remission is evalu-
ated. Finally, as expected from previous studies [11,35],
mean PSP scores obtained were unfailingly significantly
higher among remitters than non-remitters, a finding that
in our study was independent of the remission criteria,
although the magnitude of differences in mean scores
varied largely according to criteria adopted in evaluating
clinical remission. Indeed, the effect sizes for remission
evaluated by means of RSWGcr, PANNS-PNScr and
PANSS-TScr were 1.06, 1.31 and 1.58 respectively for the
‘socially useful activities’ dimension, 0.73, 0.80 and 0.92 for
‘social relationships’, and 0.83, 1.01 and 1.45 for PSP total
Table 4 Results at PSP scale in remitted and non-remitted patients according to different criteria
Items Criteria of Remission Remitted Non-remitted Statistics(df)/Cohen’s d
PSP –activities (Means ± SD) SWGC* 1.88 (1.27) 3.20 (1.21) t(110) = 5.642,p < .0001/−1.06
PANSS PNS** 1.51 (1.21) 3.08 (1.18) t(110) = 6.660,p < .0001/−1.31
PANSS TS*** 1.15 (1.05) 2.95 (1.22) t(110) = 6.814,p < .0001/−1.58
PSP-social rel (Means ± SD) SWGC* 2.02 (1.15) 2.86 (1.15) t(110) = 5.642,p < .0001/−0.73
PANSS PNS** 1.80 (21.14) 2.73 (1.17) t(110) = 3.600,p < .001/-0.81
PANSS TS*** 1.65 (1.02) 2.67 (1.18) t(110) = 3.975,p < .0001/-0.92
PSP -self care (Means ± SD) SWGC* 0.34 (0.69) 0.80 (1.16) t(110) = 2.559,p < .012/-0.48
PANSS PNS** 0.26 (0.55) 0.74 (1.12) t(110) = 2.537,p = .013/−0.54
PANSS TS*** 0.31 (0.62) 0.65 (1.06) t(110) = 2.062,p = .043/−0.39
PSP -aggressive and disturbing behaviour
(Means ± SD)
SWGC* 0.14 (0.44) 0.50 (0.81) t(110) = 2.896,p < .005/−0.55
PANSS PNS** 0.10 (0.38) 0.44 (0.764) t(110) = 2.575,p = .011/−0.56
PANSS TS*** 0.08 (0.27) 0.40 (0.40) t(110) = 2.145,p = .034/-057
PSP Total Score (Means ± SD) SWGC* 62.27 (13.65) 50.38 (14.79) t(110) = 4.419,p < .0001/0.83
PANSS PNS** 65.38 (13.13) 51.48 (14.34) t(110) = 5.032,p < .0001/1.00
PANSS TS*** 69.77 (8.63) 52.26 (14.67) t(110) = 5.783,p < .0001/1.45
PSP Total Pts with a score ≥70 (N, %) SWGC* 18 (32.1) 5 (8.9) χ2(1) = 7.879,p = .005
PANSS PNS** 16 (42.1) 6 (8.3) χ2(1) = 15.988,p < .0001
PANSS TS*** 14 (53.8) 9 (10.4) χ2(1) = 20.442,p < .0001
PSP –activities Pts with score <3 (N, %) SWGC* 26 (46.4) 5 (8.9 %) χ2(1) = 17.841,p < .0001
PANSS PNS** 23 (58.9) 13 (15.1) χ2(1) = 18.907,p < .0001
PANSS TS*** 18 (69.2) 13 (15.1) χ2(1) = 26.565,p < .0001
PSP –social rel Pts with score < 3 (N, %) SWGC* 18 (32.2) 7 (12.5) χ2(1) = 5.149 p = .023
PANSS PNS** 13 (33.3) 12 (16.4) χ2(1) = 3.562 p = .059
PANSS TS*** 16 (61.5) 15 (17.4) χ2(1) = 17.253 p < .0001
PSP –self care Pts with score < 3 (N, %) SWGC* 51 (91.1) 46 (82.1) χ2(1) = 1.650 p = .199
PANSS PNS** 37 (94.8) 60 (82.2) χ2(1) = 3.936,p = .047
PANSS TS*** 24 (92.3) 73 (84.9) χ2(1) = 0.417,p = .518
PSP -aggressive and disturbing behaviour
Pts with score < 3 (N, %)
SWGC* 54 (96.4) 49 (87.5) χ2(1) = 1.650 p = .165
PANSS PNS** 3 (94.8) 73 (100.0) χ2(1) = 0.111,p = .738
PANSS TS*** 26 (100.0) 77 (89.5) χ2(1) = 1.712,p = .191
*SWGC Schizophrenia Working Group Severity Criterion.
**PANSSPNS PANSS Positive and Negative Scores Severity Criterion.
***PANSSTS PANSS TOTAL Score Severity Criterion.
Table 5 Sensitivity, Specificity and Predictive Value Analysis of the ability of the 3 definitions of Remission to predict
good functional and cognitive outcomes
Remission criteria Sensitivity (%) Specificity (%) PPV (%) NPV (%) AUROC Youden’s J
PSP SwGc* 78 57 32 91 0.68 0.36
PANSS PNS** 74 75 44 92 0.75 0.50
PANSS TS*** 61 87 54 90 0.74 0.47
BACS SWGc* 59 53 27 81 0.56 0.12
PANSSPNS** 55 70 35 84 0.62 0.25
PANSS TS*** 41 80 38 82 0.60 0.21
*SWGC Schizophrenia Working Group Severity Criterion.
**PANSSPNS PANSS Positive and Negative Scores Severity Criterion.
***PANSSTS PANSS TOTAL Score Severity Criterion.
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evaluate clinical remission is associated with a better
assessment of how patients function in everyday life.
Our findings also support the hypothesis that patients
in remission according to more restrictive criteria display
a better neurocognitive functioning, which may explain, at
least in part, the improved vocational functioning of these
patients [36].
In order to better investigate whether the remission
criteria proposed would reflect differences in outcome
we performed a series of specific analyses. Comparing
RSWGcr, PANSS-PNScr and PANSS-TScr on their ability
to identify patients with better functional and cognitive
outcomes, the assessment of sensitivity, specificity, pre-
dictive value, and ROC analysis showed that PANSS-
PNScr is characterized by the best performances. Using
regression analysis, only PANSS-TScr remission is a
significant predictor of functioning, while all remission
criteria used in this study predicted cognitive outcome.
The general linear model analysis adopted to further
investigate the effect of different clinical remission criteria
demonstrates a significant effect of remission class both
on functioning and cognition, with patients judged as
remitted according to PANNS-TScr showing significantly
higher scores than those of patients, both remitted and
non remitted, according to RSWGcr, but not exceeding
scores of patients non-remitted according to PANSS-
PNScr. Overall, these results confirm that the best predic-
tion of functioning and, at least in part, of cognition, is
achieved using remission criteria based on the use of all
items of PANSS, followed by criteria based on the use of
positive and negative items of the same scale.
Prior to drawing conclusions, several limitations char-
acterizing the present study should be considered. First,
the sample size of the study was rather limited; second,
it focused solely on chronic outpatients who referred to
the centre over a specific period, thus excluding patients
who had moved away, refused to continue treatment or no
longer needed continuing care. Therefore, the findings
emerging from the study should be applied only to chronic
patients undergoing long-term treatment. Additionally, as
sample heterogeneity is considered one of the main flaws
of remission studies [10], it should be taken into account
how the present study included patients affected by
both schizophrenia and schizoaffective disorders. Al-
though remission rates observed were consistently, but
not significantly, higher among patients with schizoaffective
disorders, this should not detract from the relevance of
our results, in view of the effective difference in remission
rates between the two diagnostic groups independent of
remission criteria adopted. The fact that the criterion of
severity alone, without duration, was used in evaluating
remission should be taken into account; indeed, this
limitation prevented the drawing of any firm conclusionsas to the validity of complete remission criteria. However,
considering that remission studies generally demonstrate
how use of the severity criterion alone is associated with
higher remission rates [10] compared to use of both
the severity and duration criteria, it is to be expected
that if the time component is taken into account, the
rates of remission found should be even lower. There
is however no reason why that the proportional lower-
ing of rates found in this study as the severity remission
criteria became more stringent should not be confirmed,
even if the time component is adopted in evaluating
remission.
Lastly, in evaluating predictive factors for functioning
and cognitive status, other important factors (i.e. pre-
morbid IQ and premorbid functioning) which may be
significantly involved, were not taken into consideration.
Even in the light of these limitations however, the evidence
obtained would seem to be of interest.
As expected from longitudinal studies demonstrating a
clear positive correlation between severity of psychopath-
ology and levels of impairment in psychosocial functioning
[37], the present study confirmed the validity of severity
remission criteria proposed by the RSWG, associated with
a better symptomatologic and functional profile. The re-
sults obtained moreover lent further support to the find-
ings of Van Os et al. [7], who reported how the use of
standardized remission criteria in schizophrenia “had the
potential to improve documentation of clinical status in
medical records, by providing an objective measure of
illness course and treatment effect that is applicable to
routine clinical care”. Moreover, our data indicate that the
use of all items of Negative and Positive Scales of PANNS,
and particularly of the entire PANSS scale, seem to be
associated with a better identification of truly “remitted”
patients, at least when taking into consideration a better
personal, social and cognitive functioning as expression of
remission. The use of these criteria does not imply a risk
of achieving unrealistic results; indeed, the adopting of
more restrictive severity criteria was not associated with
a drastic reduction of remission rates. However, further
studies should be undertaken to evaluate the extent to
which use of the six-month duration criterion, in addition
to the more restrictive severity criterion adopted in this
study, may elicit a decrease in remission rates, particularly
as remission studies evaluated according to the criteria of
Andreasen et al. generally demonstrate that the use of
both severity and duration criteria results in the finding of
lower remission rates compared to the use of the severity
criterion alone [10]. Nonetheless, even taking into account
the latter possibility, there is no reason to suggest that the
conclusions of our study, and in particular performance of
the different sets of PANSS-based remission criteria would
not be confirmed even when taking into account the time
component.
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In conclusion, the data obtained in this study underline
the feasibility of using the entire PANSS scale to evaluate
clinical remission, at least in a research context, al-
though the authors are fully aware of the difficulties of
implementing a similar method of evaluation in routine
clinical settings. Indeed, in our experience, the time
commitments involved in assessing remission according
to SRWG criterion is approx 5–10 minutes, respect to
approx. 20–25 and 30–35 minutes, respectively, using
PANSS PNS and PANSS TS. Accordingly, we acknowledge
that “rather than a substitute for the 30 items of PANSS,
development of a concise outcome measure for remission
would create a benchmark for treatment and maintenance
goals in clinical research and general practice” [33].
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
FP participated to the design and coordination of the study, and helped to
draft the manuscript, MT participated to manage the data base of the study,
to the statistical analysis and helped to draft the manuscript, MB participated
to the statistical analysis and helped to draft the manuscript, RC participated
to the study design and to the draft of the manuscript, BC conceived the
study, participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors wish to thank the other components of the Cagliari Recovery
Study Group for their contribution to data collection: Davide Aru, Chiara
Bandecchi, Elena Corda, Luca Deriu, Enrica Diana, Francesca Fatteri, Alice
Ghiani, Alice Lai,Serena Lai, Lorena Lai, Tiziana Lepori, Raffaella Maccioni,
Paola Milia, Valeria Perra, Sonia Pintore, Silvia Pirarba, Elisabetta Piras, Sara
Piras, Laura Puddu, Rachele Pisu Randaccio, Lucia Sanna, Elisabetta Sarritzu,
Manuela Taberlet, Cristina Tocco, Enrico Zaccheddu, and Ms Anne Farmer for
language editing of the English version of the paper.
Author details
1Department of Public Health, Clinical and Molecular Medicine-Section of
Psychiatry, University of Cagliari, Via Liguria 13, 09127 Cagliari Italy.
2Department of Clinical Neurosciences, San Raffaele Scientific Institute, Via
Stamira d’Ancona 20, 20127 Milan, Italy. 3Institute for Advanced Study, IUSS,
Center for Neurolinguistics and Theoretical Syntax (NeTS), Pavia, Italy.
Received: 22 May 2013 Accepted: 24 September 2013
Published: 26 September 2013
References
1. Lysaker PA, Roe D, Buck KD: Recovery and wellness amidst schizophrenia:
definitions, evidence, and the implications for clinical practice.
J Am Psych Nurs Ass 2010, 16:36–42.
2. Lysaker PA, Taylor A, Miller A, Beattie N, Strasburger A, Davis LW: The scale
to assess narrative development: association with other measures of self
and readiness for recovery in schizophrenia spectrum disorders. J Nerv
Ment Dis 2006, 194:223–225.
3. Slade M: Personal recovery and mental illness: a guide for mental health
professionals. Cambridge UK: Cambridge University Press; 2009.
4. Roe D, Mashiach-Eizenberg M, Lysaker PH: The relation between objective
and subjective domains of recovery among persons with schizophrenia-
related disorders. Schiz Res 2011, 131:133–138.
5. Nasrallah HA, Lasser R: Improving patients’ outcomes in schizophrenia:
achieving remission. J Psychopharmacol 2006, 20(6 Suppl):57–61.
6. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger
DR: Remission in schizophrenia: proposed criteria and rationale for
consensus. Am J Psychiatry 2005, 162:441–449.7. Van Os J, Burns T, Cavallaro E, Leucht S, Peuskens J, Helldin L, Bernardo M,
Arango C, Fleishhacker W, Lachaux B, Kane JM: Standardized remission
criteria in schizophrenia. Acta Psych Scand 2006, 113:91–95.
8. Emsley R, Chiliza B, Asmal L, Lelhoenya K: The concepts of remission and
recovery in schizophrenia. Curr Opin Psychiatry 2011, 24:114–121.
9. AlAqueel B, Margolese HC: Remission in schizophrenia: critical and
systematical review. Harv Rev Psychiatry 2012, 20:281–297.
10. Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D: Remission in
Schizophrenia: validity, frequency, predictors and patients’ perspectives
5 years later. Dialogues Clin Neurosci 2010, 12:393–407.
11. Karow A, Moritz S, Lambert M, Schottle D: Naber D and EGOFORS
initiative, remitted but still impaired? Symptomatic versus functional
remission in patients with schizophrenia. Eur Psychiatry 2012, 27:401–405.
12. Oorshot M, Lataster T, Thewissen V, Lardinois M, van Os J, Delespaul PA,
Myin-Germeys I: Symptomatic remission in psychosis and real-life
functioning. Br J Psychiatry 2012, 201:215–220.
13. Carpiniello B, Pinna F, Tusconi M, Zaccheddu E, Fatteri F: Gender
differences in remission and recovery of schizophrenic and
schizoaffective patients: preliminary results of prospective cohort study.
Schiz Res Treat 2012, 2012:576369. 10.1155/2012/576369.
14. First MB, Spitzer RL, Williams JBW, Gibbon M: Structured Clinical Interview for
DSM IV Axis I Disorders (SCID-I), Versione Italiana a cura di Mazzi F, Morosini P,
De Girolamo G, Lusetti M, Guaraldi P. Firenze: Organizzazioni Speciali; 2000.
15. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin L: Structured Clinical
Interview for DSM IV Axis II Personality Disorders, Versione Italiana a cura di
Mazzi F, Morosini P, De Girolamo G, Lusetti M, Guaraldi P. Firenze:
Organizzazioni Speciali; 2003.
16. First MB, Spitzer RL, Williams JBW, Gibbon M: Structured clinical interview for
DSM IV axis I disorders-resarch version (SCID-I, version 2. 0). New York:
Biometrics Research Department, New York State Psychiatric Institute; 1996.
17. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin L: Structured clinical
interview for DSM IV axis II personality disorders – research version (SCID II,
version 2.0). New York: Biometrics Research Department, New York State
Psychiatric Institute; 1996.
18. Pancheri P, Brugnoli R, Carilli L, Delle Chiaie R, Marconi PL, Petrucci RM:
Valutazione dimensionale della sintomatologia schizofrenica. Validazione
della versione italiana della scala per la valutazione dei sintomi positivi e
negativi (PANSS). Giorn Ital Psicopat 1995, 1:60–75.
19. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophr Bull 1987, 13:261–276.
20. Kay SR, Opler RA, Fiszbein A: The structured clinical interview for positive and
negative syndromes of schizophrenia. Versione Italiana a cura di Migone P.
Parma: Università di Parma; 1999.
21. Kay SR, Opler RA, Fiszbein A: The structured clinical interview for positive and
negative syndromes of schizophrenia. New York: Multi-Health Systems; 1992.
22. Kay SR, Opler RA, Fiszbein A, Ramirez PM: Positive and negative syndrome
scale (PANSS) technical manual. New York: Multi-Health System; 2006.
23. Wallwork RS, Fortgang R, Hashimoto R, Weingerger DR, Dickinson B:
Searching for a consensus five-factor model of the positive and negative
scale for schizophrenia. Schizophr Res 2012, 137:246–250.
24. Haro JM, Kamath SA, Ochoa S, et al: The clinical global impression-
schizophrenia scale: a simple instrument to measure the diversity of
symptoms present in schizophrenia. Acta Psychiatr Scand 2003,
416(Suppl):16–23.
25. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe PM, Coughnenour L: The
brief assessment of cognition in schizophrenia: reliability, sensitivity and
comparison with a standardized neurocognitive battery. Schizophr Res
2004, 68:283–297.
26. Anselmetti S, Poletti P, Ermoli E, Bechi M, Cappa S, Venneri A, Smeraldi E,
Cavallaro R: The brief assessment of cognition in schizophrenia.
Normative data for the Italian population. Neurol Sci 2008, 29:85–92.
27. Folstein MF, Folstein SE, McHugh PR: “Mini mental state”. a practical
method for grading the cognitive state of patients for the clinician.
J Psychiatr Res 1975, 12:189–198.
28. Measso G, Cavarzeran F, Zappalà G, Lebowitz BD, Crook TH, Pirozzolo FS,
Amaducci L, Massari D, Grigoletto F: The mini mental state examination.
Normative study of an Italian random sample. Dev Neuropsychol 1993, 9:77–85.
29. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R: Development,
reliability and acceptability of a new version of the DSM-IV social and
occupational functioning assessment scale (SOFAS) to assess routine
social functioning. Acta Psychiatr Scand 2000, 2000(101):323–329.
Pinna et al. BMC Psychiatry 2013, 13:235 Page 10 of 10
http://www.biomedcentral.com/1471-244X/13/23530. Cassidy CM, Norman R, Manchanda R, Schmitz N, Malla A: Testing
definitions of symptom remission. Schizophr Bull 2010, 36:1001–1008.
31. Van Os J, Drukker MA, Campo J, Meijer J, Back M, Delespaul P: Validation of
remission criteria for schizophrenia. Am J Psychiatry 2006, 163:2000–2002.
32. Beintinger R, Lin J, Kissling W, Leucht S: Comparative remission
frequencies of schizophrenic patients using various remission criteria.
Prog Neuropshychopharmacol Biol Psychiatry 2008, 32:1643–1651.
33. Opler MGA, Yang LH, Caleo S, et al: Statistical validation of the criteria for
symptom remission in schizophrenia: preliminary findings. BMC Psychiatry
2007, 7:35.
34. Green MF, Kermn RS, Braff DL, Mintz J: Neurocognitive deficits and
functional outcome in schizophrenia: are we measuring the “right stuff”?
Schizophr Bull 2000, 26:119–136.
35. Brissos S, Videira Dias V, Balanzà-Martinez V, Carita AI, Figueira ML:
Symptomatic remission in schizophrenia patients: relationship with
social functioning, quality of life, and neurocognitive performance.
Schizophr Res 2011, 129:133–136.
36. McGurk SR: Neurocognition as a determinant of employments status in
schizophrenia. J Psychiatr Pract 2000, 6:190–196.
37. Bottlender R, Strauss A, Moller HJ: Association between psychopathology
and problems of psychosocial functioning in the long term outcome of
patients diagnosed with schizophrenic, schizoaffective and affective
disorders. Eur Arch Psychiatry Clin Neurosci 2013, 263:85–92.
doi:10.1186/1471-244X-13-235
Cite this article as: Pinna et al.: Criteria for symptom remission revisited:
a study of patients affected by schizophrenia and schizoaffective
disorders. BMC Psychiatry 2013 13:235.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
